A prospective case series of 56 eyes undergoing Paul glaucoma implant (PGI; Advanced Ophthalmic Innovations) surgery has demonstrated the medium-term safety and efficacy of the procedure, according to researchers at the University Eye Hospital Bonn in Germany. This study, conducted between April and September 2021, provides key insights into PGI outcomes in a predominantly White population.

At the 2-year mark, researchers reported significant reductions in IOP, with average levels decreasing from 25.43 mmHg preoperatively to 11.25 mmHg, a 50% reduction. Use of IOP-lowering drops dropped from an average of 3.5 medications per patient to 0.46 medications. Success rates varied based on IOP thresholds, with the highest rates seen at IOP ≤21 mm Hg (89% qualified success). Use of an intraluminal prolene stent in 42.9% of eyes was associated with preventing early hypotony and facilitating subsequent IOP reductions.

The findings from the study, published in the Journal of Glaucoma, suggest that PGI surgery is an effective option for managing glaucoma, though longer-term studies are needed to further evaluate its role in clinical practice.